Contribute Try STAT+ Today

In the latest state effort to peel back the curtain on drug pricing, Nevada has adopted a law that requires pharmaceutical companies to disclose prices and costs associated with their asthma medicines, a step that mirrors action taken two years ago on diabetes treatments.

Specifically, drug makers must submit reports to the state detailing costs for producing or acquiring medicines used to treat asthma, as well as profit margins, any financial assistance provided to patients, and the factors contributing to recent, significant price increases.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.